17β-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 10, 2007, Pages 972-978

  Chen, Lu ^a   Liu, Yuan ^a   Cui, Bota ^a   Mi, Qiongyu ^a   Huang, Yan ^a   Fan, Leming ^a   Chen, Qi ^a   Tang, James ^b   Ferro, Albert ^c   Ji, Yong ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Obsidian Research Limited   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

17 oestradiol; Advanced glycation end products; Aggregation; cGMP; Nitric oxide; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; ANTIESTROGEN; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; FULVESTRANT; N ACETYLGLUCOSAMINE; NITRIC OXIDE; PHOSPHOSERINE; SERINE; DRUG DERIVATIVE; ENZYME INHIBITOR;

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GLYCOSYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; WESTERN BLOTTING; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IN VITRO STUDY; ISOLATION AND PURIFICATION; METABOLISM; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; STATISTICAL ANALYSIS;

ACETYLGLUCOSAMINE; ADULT; BLOOD PLATELETS; BLOTTING, WESTERN; CYCLIC GMP; DATA INTERPRETATION, STATISTICAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PHOSPHOSERINE; PLATELET AGGREGATION;

EID: 34547972464     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04680.x     Document Type: Article

References (25)

1. Randriamboavonjy V, Fleming I. Endothelial nitric oxide synthase (eNOS) in platelets: How is it regulated and what is it doing there? Pharmacol. Rep. 2005 57 59 65.
2. Erhardt LR. Women: A neglected risk group for atherosclerosis and vascular disease. Scand. Cardiovasc. J. 2003 37 : 3 12.
3. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998 280 : 605 13.
4. Manson JE, Hsia J, Johnson KC et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 2003 349 : 523 34.
5. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004 291 : 1701 12.
6. Khetawat G, Faraday N, Nealen ML et al. Human megakaryocytes and platelets contain the estrogen receptor and androgen receptor (AR): Testosterone regulates AR expression. Blood 2000 95 : 2289 96.
7. Jayachandran M, Miller VM. Human platelets contain estrogen receptor α, caveolin-1 and estrogen receptor associated proteins. Platelets 2003 14 : 75 81.
8. Aldrighi JM, Oliveira RL, D'amico E et al. Platelet activation status decreases after menopause. Gynecol. Endocrinol. 2005 20 : 249 57.
9. Jayachandran M, Mukheriee R, Sterinkamp T et al. Differential effects of 17beta-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. Am. J. Physiol. Heart Circ. Physiol. 2005 288 : H2355 62.
10. Nakano Y, Oshima T, Matsuura H et al. Effect of 17β-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis. Arterioscler. Thromb. Vasc. Biol. 1998 18 : 961 7.
11. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ. Res. 2000 87 : 840 4.
12. Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc. Diabetol. 2003 2 : 2.
13. Monti LD, Barlassina C, Citterio L et al. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes 2003 52 : 1270 5.
14. Xu B, Ji Y, Yao K et al. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: Relevance to diabetes. Clin. Sci. 2005 109 : 439 46.
15. Hasegawa Y, Sueiro A, Higasa S et al. Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. Thromb. Res. 2002 107 : 319 23.
16. Meng D, Liu N. Expression of platelet-endothelial cell adhesion molecule-1 in human umbilical vein endothelial cells by exposure to advanced glycosylation end products and inflammatory mediators. Chin. Med. J. 2003 116 : 1336 40.
17. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 1995 46 : 223 34.
18. Sogo N, Magid KS, Shaw CA et al. Inhibition of human platelet aggregation by nitric oxide donor drugs: Relative contribution of cGMP-independent mechanisms. Biochem. Biophys. Res. Commun. 2000 279 : 412 19.
19. Xu B, Chibber R, Ruggiero D et al. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 2003 17 : 1289 91.
20. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003 284 : R1 12.
21. Du XL, Edelstein D, Dimmeler S et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 2001 108 : 1341 8.
22. Federici M, Menghini R, Mauriello A et al. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 2002 106 : 466 72.
23. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins. Signal transduction and O-GlcNAc. Science 2001 291 : 2376 8.
24. Wyatt AW, Steinert JR, Mann GE. Modulation of the l-arginine/nitric oxide signalling pathway in vascular endothelial cells. Biochem. Soc. Symp. 2004 71 : 143 56.
25. Colhoun H. Coronary heart disease in women: Why the disproportionate risk? Curr. Diab. Rep. 2006 6 : 22 8.